Research-based content. This article is based on published research and publicly available pricing data. It is not medical advice. Do not start, stop, or change any medication without consulting a licensed healthcare professional. See sources below.
Difamilast (Adquey) in India — Non-Steroidal Eczema Treatment Price & Alternatives
Approximate Price Comparison (per month supply)
India
$5 – $15
US
$500 – $800
UK
$150 – $300
Prices are approximate and vary by dosage, brand, and pharmacy. Based on publicly available data.
Indian Manufacturers
The FDA approved Adquey (difamilast 1% ointment) on February 13, 2026 — a non-steroidal topical treatment for mild-to-moderate atopic dermatitis. In the US, a single tube costs $500–$800. In India, equivalent non-steroidal eczema treatments cost $5–$15.
Why Difamilast Matters
Atopic dermatitis (eczema) affects 230 million people globally. Most are managed with topical corticosteroids — effective for flares but problematic for long-term use:
- Skin thinning (atrophy) with prolonged use
- Rebound flares when stopped
- Restricted use on face, eyelids, and skin folds
Difamilast is a PDE4 inhibitor that reduces inflammation without steroid-related side effects. It was already approved in Japan in 2021, where it has been used successfully for 5 years. The US approval in 2026 brings it to a much larger market — at a much higher price.
India’s Non-Steroidal Eczema Options
Indian patients have had access to affordable non-steroidal eczema treatments for years:
| Treatment | US Monthly Cost | India Monthly Cost | Type |
|---|---|---|---|
| Adquey (difamilast) | $500 – $800 | Not yet launched | PDE4 inhibitor |
| Crisaborole (Eucrisa) | $600 – $900 | $10 – $20 (generic) | PDE4 inhibitor |
| Tacrolimus 0.1% | $200 – $400 | $3 – $8 | Calcineurin inhibitor |
| Pimecrolimus 1% | $300 – $500 | $5 – $12 | Calcineurin inhibitor |
| Dupilumab (injection) | $3,000 – $3,500 | $300 – $600 | IL-4/13 blocker |
Indian generic manufacturers like Glenmark (a global leader in dermatology) and Sun Pharma produce these at scale for domestic and export markets.
Dermatology Medical Tourism to India
India has become a destination for patients with chronic skin conditions:
Common reasons international patients visit:
- Cost of biologics: Dupilumab (Dupixent) for severe eczema costs $36,000–$42,000/year in the US vs $3,600–$7,200/year in India
- Ayurvedic + modern combination therapy: Some patients seek integrative approaches available at centers like AIIMS Delhi and CMC Vellore
- Phototherapy courses: Narrowband UVB treatment for eczema/psoriasis at $5–$15 per session vs $200–$500 in the US
- Medication stockpiling: A 6-month supply of non-steroidal topicals costs less than one US tube
Top dermatology hospitals for international patients:
- AIIMS New Delhi — India’s premier government hospital, leading dermatology research
- Manipal Hospital Bengaluru — JCI-accredited, international patient wing
- Apollo Hospitals Chennai — Comprehensive dermatology with cosmetic services
- Amrita Hospital Kochi — NABH-accredited, dedicated skin disease department
The Chronic Condition Economics
Eczema is lifelong. The cumulative cost difference is staggering:
10-year treatment cost (moderate eczema, maintenance therapy):
| Treatment Path | US Cost | India Cost |
|---|---|---|
| Non-steroidal topical (daily use) | $60,000 – $96,000 | $600 – $1,800 |
| Biologic (dupilumab, severe cases) | $360,000 – $420,000 | $36,000 – $72,000 |
| Annual dermatologist visits (2x/year) | $6,000 – $10,000 | $120 – $240 |
For patients managing chronic eczema without adequate insurance, India’s pharmaceutical pricing makes the difference between treatment and going without.
Sources & References
- FDA Approval — Adquey (difamilast 1%) Ointment, February 13, 2026, for mild-to-moderate atopic dermatitis
- Japanese Dermatological Association — Difamilast clinical data (approved in Japan 2021)
- Indian Journal of Dermatology — Atopic dermatitis treatment guidelines, 2025
- Glenmark Pharmaceuticals — Dermatology portfolio, 2026
- NPPA — Price control on dermatological formulations, India
Frequently Asked Questions
What is Difamilast (Adquey) and what does it treat?
Difamilast is a non-steroidal topical PDE4 inhibitor approved by the FDA on February 13, 2026 for mild-to-moderate atopic dermatitis (eczema). It was previously available in Japan since 2021. Unlike topical steroids, it does not cause skin thinning with long-term use, making it suitable for sensitive areas like the face and skin folds.
How much does eczema treatment cost in India vs the US?
In the US, Adquey costs $500–$800 per tube. In India, PDE4 inhibitor topicals and equivalent non-steroidal eczema treatments cost $5–$15. Indian dermatologists also prescribe tacrolimus and pimecrolimus (non-steroidal immunomodulators) at $3–$10 per tube — treatments that cost $200–$400 in the US.
Are there Indian alternatives to Adquey for eczema?
Yes. Indian pharmaceutical companies manufacture crisaborole (another PDE4 inhibitor), tacrolimus ointment, and pimecrolimus cream — all non-steroidal eczema treatments — at 90-95% lower cost than US brands. Generic difamilast is expected from Indian manufacturers once the formulation is registered with CDSCO.
Why do medical tourists come to India for dermatology treatment?
India has world-class dermatologists at a fraction of Western costs. A full dermatology consultation with patch testing, biopsy if needed, and 6-month medication supply costs $100–$300 in India vs $2,000–$5,000 in the US. For chronic conditions like eczema, psoriasis, and vitiligo, Indian treatment courses save thousands annually.
Is difamilast better than topical steroids for eczema?
Difamilast is not necessarily more effective than potent topical steroids for acute flares, but it offers a crucial advantage: no risk of skin atrophy (thinning) with long-term use. This makes it ideal for maintenance therapy on the face, eyelids, groin, and axillae where steroids cause damage over time. It fills a gap between weak OTC steroids and systemic immunosuppressants.
Disclaimer: This content is for informational and educational purposes only, based on published research and publicly available data. It does not constitute medical advice, diagnosis, or treatment recommendations. Drug prices are approximate and vary by dosage, formulation, brand, and pharmacy. Always consult a qualified healthcare professional before making any decisions about medication. Fittour India is not a pharmacy, drug seller, or licensed medical provider.